Pharmaceutical 3630 articles

Beasley Allen has one of the largest and most technologically advanced Mass Torts practices in the country. The Mass Torts division represents numerous people in claims against companies that manufacture and/or market defective pharmaceuticals and/or medical devices. The resources devoted to this division allow the firm to competently and conscientiously handle any group of cases, no matter how large, along with particular catastrophic injury cases.

Our firm was recently involved in one of the greatest victories in Mass Torts history, against drug manufacturer Merck regarding the drug Vioxx. After more than five years of hard-fought and difficult litigation, Merck agreed to pay $4.85 billion, the largest pharmaceutical settlement in U.S. history, to resolve certain Vioxx-related claims involving plaintiffs who suffered a heart attack, including sudden cardiac death, or a stroke.

Woman who fought to ban power morcellator faces cancer recurrence


The doctor who launched a campaign to ban a commonly used gynecology surgical tool called a power morcellator because it can spread undetected uterine cancer and worsen a woman’s odds of survival, announced she has suffered a recurrence of the deadly disease. Amy Reed, 41, did not set out to be an advocate for women’s health issues. The issue sort of fell into her lap. Reed, an anesthesiologist, and her husband, a heart surgeon, live in Pennsylvania with their six children. In October 2013, Reed underwent a hysterectomy to remove what doctors thought were benign uterine fibroids. Doctors removed her uterus using ... Read More

Bayer banks on sales of blood thinner Xarelto


Bayer announced it plans to increase sales for its main Healthcare division by 6 percent on average through 2017 to more than $26.7 billion by hanging its hat on new drugs, such as the blood thinner Xarelto. The company says rising sales of these newer drugs have helped offset declines of its birth control pill and multiple sclerosis treatment in the face of competition. Bayer teamed up with Johnson & Johnson subsidiary Janssen Pharmaceuticals to produce Xarelto, which became the second drug in a new class of blood thinners called Xa inhibitors. The anticoagulant is used to prevent or treat blood ... Read More

Viagra users should use sunscreen, limit sun exposure


The warmer season brings many people back outdoors to soak up the sun’s rays, but some people should be more vigilant than others about using sunscreen to protect against skin cancer. Studies show that men who currently use or have ever used the erectile dysfunction drug Viagra are at much higher risk of developing melanoma, the deadliest form of skin cancer. Viagra, known generically as sildenafil, is in a class of drugs known as phosphodiesterase 5A (PDG5A) inhibitors. This class of drugs also includes Cialis (tadalafil) and Levitra (vardenafil). The medications affect the same genetic pathway that allows skin cancer ... Read More

Another lawsuit filed in wake of superbug outbreak


A Washington state woman has filed a lawsuit against the makers of a specialized endoscope blamed for a life threatening superbug outbreak in some medical facilities, alleging she became infected at Harborview Medical Center in Seattle two years ago. The hospital, however, says it has no record of a carbapenem-resistant Enterobacteriaceae (CRE) infection caused by the medical devices. Debbie Newton, 54, claims she contracted CRE after undergoing a procedure with a duodenoscope made by Olympus America Inc. on Feb. 7, 2013. Duodenoscopes are a type of endoscope that is fed down patients’ throats to treat or diagnose various gastrointestinal ailments. About ... Read More

Louisiana woman sues Xarelto makers over bleeding risks


A Louisiana woman is suing the makers of the blood thinner Xarelto claiming she was never warned that using the drug could cause her to suffer serious, uncontrolled bleeding. According to the lawsuit, Deborah Lyons was prescribed Xarelto in March 2014 by her doctor to prevent strokes. While using the drug, Lyons suffered three severe bleeding events and had to be hospitalized to receive blood transfusions on three separate occasions. Xarelto is used to prevent or treat blood clots and strokes in some heart patients, and blood clots in patients who recently underwent knee or hip replacement surgery. It was approved ... Read More

Abnormal heartbeat, death associated with hepatitis C drugs


Nine patients taking the hepatitis C drug Harvoni or Sovaldi who were also taking the heart medication amiodarone experienced abnormally slow heart rhythms, resulting in three patients needing pacemakers and one person dying of cardiac arrest. Gilead Sciences Inc. notified health care professionals of this alarming side effect last week. Specifically, six cases of symptomatic bradycardia occurred within the first 24 hours of treatment being initiated and the other three within the first two to 12 days after treatment. All patients were taking amiodarone, a drug used to treat heart rhythm abnormalities, also known as arrhythmias. Brand names include Cordarone, ... Read More

Study reveals most people hate idea of taking daily medication


A recent study conducted by researchers with the University of California reveals the lengths people are willing to go to avoid taking daily medication. One-third of people surveyed said they would rather risk an early death than take a daily pill to prevent heart disease, and a fifth of those polled would pay at least $1,000 to avoid taking medication daily. The survey was initially designed to see just how much time at the end of their lives people would be willing to give up to avoid taking preventative medications every day, and how much they would be willing to pay to ... Read More

More patients eligible for metal-on-metal hip injury compensation

hip implant

An additional 1,400 patients who had received a DePuy ARS metal-on-metal hip implant are now eligible to participate in the U. S. Settlement Program to receive compensation for their revision surgeries. DePuy Orthopaedics, a subsidiary of Johnson & Johnson, announced that it has agreed to extend the existing U.S. Settlement Program to include eligible patients in the U.S. who had surgery to remove and replace their defective implants after Aug. 31, 2013 and on or before Jan. 31, 2015. The previous settlement, announced in November 2013, did not compensate eligible patients who had revision surgery after Aug. 30, 2013. The agreement ... Read More

Antibiotics linked to increased risk of type 2 diabetes


People who have taken specific antibiotics repeatedly may be more likely to develop type 2 diabetes, according to a new study published in the European Journal of Endocrinology. For the study, researchers examined the number of antibiotic prescriptions among 200,000 people with diabetes at least one year before they were diagnosed with the disease. That total was compared to the number of antibiotics prescribed to 800,000 people the same average age as the previous group but who did not have diabetes. Researchers found that the more courses of antibiotics patients were prescribed, the greater their risk of diabetes. The types ... Read More

Melanoma drug proves superior in clinical trials


Merck & Co.’s cancer drug Keytruda (pembrolizumab) was superior in treating patients of advanced melanoma in phase III clinical trials compared to Bristol-Myers Squibb Co.’s Yervoy (ipilimumab). Keytruda is in a class of cancer drugs known as PD-1 inhibitors. It is currently approved for the treatment of unresectable or metastatic melanoma, and in patients whose disease has progressed after the use of the standard treatment, Yervoy. The positive results of the latest trial of Keytruda is good news for the large number of patients worldwide with skin cancer. Melanoma is the deadliest form of skin cancer because it can be ... Read More